Literature DB >> 14977622

Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.

Kian-Chung Ong1, Ai-Ching Kor, Wai-Fung Chong, Arul Earnest, Yee-Tang Wang.   

Abstract

The aim of this study is to investigate the effects of inhaled furosemide on the sensation of dyspnea produced during exercise in patients with stable chronic obstructive pulmonary disease (COPD). In a double-blind, randomized, crossover study we compared the effect of inhaled furosemide on dyspneic sensation during exercise testing with that of placebo. Spirometry and incremental and constant-load exercise testing were performed after inhalation of placebo or furosemide on 2 separate days in 19 patients with moderate or severe COPD. Subjects were asked to rate their sensation of respiratory discomfort using a 100-mm visual analog scale. There was significant improvement in mean FEV1 and FVC after inhalation of furosemide (p = 0.038 and 0.005, respectively) but not after placebo. At standardized exercise time during constant-load exercise testing but not during incremental exercise, the mean dyspneic visual analog scale score was lower after inhalation of furosemide compared with placebo (33.7 +/- 25.2 vs. 42.4 +/- 24.0 mm, respectively, p = 0.014). We conclude that inhalation of furosemide alleviates the sensation of dyspnea induced by constant-load exercise testing in patients with COPD and that there is significant bronchodilation after inhalation of furosemide compared with placebo in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977622     DOI: 10.1164/rccm.200308-1171OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

Review 1.  The role of vagal afferent nerves in chronic obstructive pulmonary disease.

Authors:  Bradley J Undem; Marian Kollarik
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  Dyspnea review for the palliative care professional: treatment goals and therapeutic options.

Authors:  Arif H Kamal; Jennifer M Maguire; Jane L Wheeler; David C Currow; Amy P Abernethy
Journal:  J Palliat Med       Date:  2012-01       Impact factor: 2.947

3.  Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness.

Authors:  Robert B Banzett; Richard M Schwartzstein; Robert W Lansing; Carl R O'Donnell
Journal:  Respir Physiol Neurobiol       Date:  2017-08-24       Impact factor: 1.931

4.  Physiological mechanisms of dyspnea during exercise with external thoracic restriction: role of increased neural respiratory drive.

Authors:  Cassandra T Mendonca; Michele R Schaeffer; Patrick Riley; Dennis Jensen
Journal:  J Appl Physiol (1985)       Date:  2013-12-19

5.  The Effect of Aerosol Saline on Laboratory-Induced Dyspnea.

Authors:  C R O'Donnell; R W Lansing; R M Schwartzstein; Robert Banzett
Journal:  Lung       Date:  2016-12-21       Impact factor: 2.584

6.  Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease.

Authors:  Nicholas T Vozoris; Xuesong Wang; Peter C Austin; Denis E O'Donnell; Shawn D Aaron; Teresa M To; Andrea S Gershon
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

7.  Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness.

Authors:  Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2017-10-12       Impact factor: 1.931

8.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

9.  An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

Authors:  Mark B Parshall; Richard M Schwartzstein; Lewis Adams; Robert B Banzett; Harold L Manning; Jean Bourbeau; Peter M Calverley; Audrey G Gift; Andrew Harver; Suzanne C Lareau; Donald A Mahler; Paula M Meek; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2012-02-15       Impact factor: 21.405

Review 10.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.